下一代免疫療法市場規模、佔有率和成長分析：按免疫療法類型、疾病、給藥途徑、最終用戶、開發階段和地區分類－2026-2033年產業預測

2024 年全球下一代免疫療法市場價值為 1,510 億美元，預計到 2033 年將從 2025 年的 1,691.2 億美元成長到 4,187.3 億美元，預測期（2026-2033 年）的複合年成長率為 12.0%。

下一代免疫療法市場由生物學洞見與工程創新融合驅動，為有效疾病管理奠定了基礎。該市場涵蓋了基因修飾細胞療法、雙特異性抗體、新抗原疫苗和免疫調節基因編輯等先進治療方法，即使在傳統治療方法無效的情況下也能提供根治性方案。該領域的發展已從基礎細胞激素療法轉向先進的CAR-T療法和mRNA疫苗的核准，從而降低了研發風險並增加了投資。可擴展平台技術和高效生產流程的興起正在改善患者的治療機會，並推動對同種異體療法和個人化mRNA疫苗的大量投資。此外，人工智慧在臨床開發中發揮著至關重要的作用，透過增強標靶發現、候選化合物設計和患者分層，加速了臨床試驗的成功和商業化進程。

全球下一代免疫療法市場成長要素

全球下一代免疫療法市場正受到工程技術、遞送方法和生物標記技術創新的顯著推動，這些創新顯著提升了治療方法的特異性、安全性和可生產性。這些技術進步能夠更精準地靶向免疫細胞和腫瘤抗原，最大限度地降低研發過程中的不確定性，並有效地彌合藥物發現到臨床應用之間的鴻溝。平台能力的提升實現了可擴展的生產流程和穩定的質量，從而吸引投資並促進了行業內的夥伴關係。這些因素共同降低了研發者的進入門檻，加速了藥物研發管線的成熟，拓寬了可治療疾病的範圍，從而推動了市場的持續成長。

全球下一代免疫療法市場面臨的限制因素

全球下一代免疫療法市場面臨許多挑戰，生產過程的複雜性和嚴格的品管措施阻礙了其廣泛應用。對專業設施和熟練人員的需求，以及對批次間產品品質一致性的要求，都增加了研發公司和契約製造所需的時間和資源。這些營運限制延緩了規模化生產進程，降低了供應鏈的適應性，並增加了產品上市的風險。因此，企業可能會放緩專案進度，僅專注於最有前景的候選藥物，或難以滿足多樣化的臨床需求，最終限制了市場成長。

下一代免疫療法市場的全球趨勢

在全球新一代免疫療法市場中，基於精準生物標記的療法已成為一大趨勢，它能夠最佳化患者篩選和治療方法設計。這種方法能夠針對特定患者族群制定個人化治療方案，最終改善臨床療效。隨著診斷檢測被整合到研發項目中，診斷和治療藥物研發人員之間的合作日益加強，加速了核准流程的協調統一，並促進了與保險公司的溝通。對伴隨診斷投入的增加，正在塑造差異化的產品定位，並透過更清晰的價值提案推動商業性化應用。因此，臨床醫生和醫療系統越來越傾向於採用利用預測性標記的治療方法，這影響著臨床試驗設計和打入市場策略，從而推動了個人化治療的發展。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球下一代免疫療法市場規模：以免疫療法類型分類

• 細胞療法
  • CAR-T細胞療法
  • TCR T細胞療法
• 單株抗體
  • 免疫查核點抑制劑
  • 抗體藥物複合體

全球下一代免疫療法市場規模：依疾病分類。

• 腫瘤學
  • 血癌
  • 固體癌
• 自體免疫疾病
  • 類風濕性關節炎
  • 多發性硬化症

全球下一代免疫療法市場規模：按給藥途徑分類

• 靜脈
• 皮下

全球下一代免疫療法市場規模：按最終用戶分類

• 醫院
• 研究機構

全球下一代免疫療法市場規模：依研發階段分類

• 臨床前階段
• 臨床試驗
  • I期試驗
  • II期試驗

全球下一代免疫療法市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Moderna, Inc.
• Novartis AG
• Gilead Sciences, Inc.
• Amgen Inc.
• Regeneron Pharmaceuticals, Inc.
• Juno Therapeutics, Inc.
• Kite Pharma, Inc.
• CRISPR Therapeutics AG
• Bluebird Bio, Inc.
• Celgene Corporation
• Adaptive Biotech
• Immunogen, Inc.
• NantKwest, Inc.
• Zymeworks Inc.
• Aimmune Therapeutics, Inc.
• OncoSec Medical Incorporated
• Obsidian Therapeutics, Inc.
• Synlogic, Inc.
• TCR2 Therapeutics Inc.
• Fate Therapeutics, Inc.

結論與建議

Global Next Generation Immunotherapies Market size was valued at USD 151.0 Billion in 2024 and is poised to grow from USD 169.12 Billion in 2025 to USD 418.73 Billion by 2033, growing at a CAGR of 12.0% during the forecast period (2026-2033).

The next-generation immunotherapies market is fueled by the integration of biological insights and engineering innovations, establishing a foundation for effective disease management. This market encompasses advanced therapies like engineered cellular treatments, bispecific antibodies, neoantigen vaccines, and immune-modulating gene edits, providing curative options in scenarios where traditional methods falter. The evolution of the field has seen significant advancements, transitioning from basic cytokine therapies to sophisticated CAR-T approvals and mRNA vaccines, leading to decreased development risks and increased investments. The rise of scalable platform technologies and efficient manufacturing processes enhances patient accessibility and promotes significant investment in allogeneic therapies and personalized mRNA vaccines. Additionally, AI is pivotal in clinical development, enhancing target discovery, candidate design, and patient stratification, thereby expediting the path to successful trials and commercialization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Immunotherapies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Immunotherapies Market Segments Analysis

Global next generation immunotherapies market is segmented by immunotherapy types, disease applications, administration routes, end users, development stages and region. Based on immunotherapy types, the market is segmented into Cellular Therapies and Monoclonal Antibodies. Based on disease applications, the market is segmented into Oncology and Autoimmune Diseases. Based on administration routes, the market is segmented into Intravenous and Subcutaneous. Based on end users, the market is segmented into Hospitals and Research Institutions. Based on development stages, the market is segmented into Preclinical and Clinical Trials. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Next Generation Immunotherapies Market

The Global Next Generation Immunotherapies market is significantly driven by innovations in engineering, delivery methods, and biomarker technologies that enhance specificity, safety, and manufacturability of treatments. These technological advancements minimize uncertainties in development by allowing for more accurate targeting of immune cells and tumor antigens, effectively bridging the gap between discovery and clinical application. Improved platform capabilities facilitate scalable processes and consistent quality, drawing in investments and fostering partnerships within the industry. Together, these factors reduce entry barriers for developers, expedite the maturation of drug pipelines, and expand the variety of treatable conditions, thus promoting ongoing market growth.

Restraints in the Global Next Generation Immunotherapies Market

The Global Next Generation Immunotherapies market faces significant challenges due to complex manufacturing processes and stringent quality control measures that hinder widespread implementation. The requirement for specialized facilities and a skilled workforce, along with the necessity for consistent product quality between batches, increases the time and resources needed for both developers and contract manufacturers. These operational constraints slow down the scaling process, limit supply chain adaptability, and raise the risks associated with bringing products to market. Consequently, businesses may choose to delay the advancement of their programs, focus solely on the most viable candidates, and struggle to fulfill varying clinical demands, ultimately restricting market growth.

Market Trends of the Global Next Generation Immunotherapies Market

The Global Next Generation Immunotherapies market is experiencing a significant trend towards precision biomarker-driven adoption, enhancing patient selection and therapeutic design. This approach facilitates tailored treatments for specific populations, ultimately improving clinical outcomes. As diagnostic assays are integrated into development programs, closer collaborations between diagnostic and therapy developers are formed, accelerating pathway alignment and fostering dialogue with payers. Increased investment in companion diagnostics is shaping differentiated product positioning and promoting commercial adoption through clearer value propositions. Consequently, clinicians and health systems are favoring therapies that leverage predictive markers, influencing trial designs and market access strategies, thereby advancing personalized therapeutic approaches.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Next Generation Immunotherapies Market Size by Immunotherapy Types & CAGR (2026-2033)

• Market Overview
• Cellular Therapies
  • CAR T-Cell Therapy
  • TCR T-Cell Therapy
• Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • Antibody-Drug Conjugates

Global Next Generation Immunotherapies Market Size by Disease Applications & CAGR (2026-2033)

• Market Overview
• Oncology
  • Blood Cancer
  • Solid Tumors
• Autoimmune Diseases
  • Rheumatoid Arthritis
  • Multiple Sclerosis

Global Next Generation Immunotherapies Market Size by Administration Routes & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous

Global Next Generation Immunotherapies Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Research Institutions

Global Next Generation Immunotherapies Market Size by Development Stages & CAGR (2026-2033)

• Market Overview
• Preclinical
• Clinical Trials
  • Phase I Trials
  • Phase II Trials

Global Next Generation Immunotherapies Market Size & CAGR (2026-2033)

• North America (Immunotherapy Types, Disease Applications, Administration Routes, End Users, Development Stages)
  • US
  • Canada
• Europe (Immunotherapy Types, Disease Applications, Administration Routes, End Users, Development Stages)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Immunotherapy Types, Disease Applications, Administration Routes, End Users, Development Stages)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Immunotherapy Types, Disease Applications, Administration Routes, End Users, Development Stages)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Immunotherapy Types, Disease Applications, Administration Routes, End Users, Development Stages)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunogen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aimmune Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoSec Medical Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Obsidian Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlogic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TCR2 Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations